Accurately detecting and quantifying tumor cells in cerebrospinal fluid (CSF) is essential for diagnosing, monitoring, and managing central nervous system (CNS) malignancies—particularly leptomeningeal metastases (LM) and other aggressive cancers that spread to the...
CNSide Diagnostics is pleased to announce a major milestone in expanding patient access to advanced CNS cancer diagnostics. Humana (NYSE: HUM)—one of the nation’s largest health insurers—has entered into a national agreement with Plus Therapeutics, providing coverage...
The Society for Neuro-Oncology (SNO) and WFNOS Annual Meeting is one of the most important gatherings of clinicians, researchers, and innovators working to improve outcomes for patients with central nervous system (CNS) cancers....
Each year, approximately 110,000 people in the United States are affected by leptomeningeal metastases (LM) — a devastating complication of advanced cancers such as breast, lung, and melanoma. Despite its prevalence, treatment options remain limited, costly, and often...
Our CNSide Diagnostics lab team brought some Halloween fun to our new Houston facility at Levit Green — a creative and spirited way to celebrate as we continue to build momentum in our new space! Beyond the costumes and candy, this moment reflects a larger milestone...
Last weekend, members of the Plus Therapeutics and CNSide Diagnostics teams, led by Gabby Cleveland, participated in the 7th Annual Head for the Cure Foundation 5K in Phoenix, Arizona — running and walking in support of brain cancer research and awareness. This event...
Plus Therapeutics (NASDAQ: PSTV) announced continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostics, and its Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory-developed test (LDT). Recent...
CNSide Diagnostics is pleased to announce the addition of Elizabeth Hernandez as Laboratory Operations Coordinator. Elizabeth brings valuable experience in laboratory management and operational excellence to our growing team — supporting CNSide’s mission to advance...
Last week, CNSide Diagnostics Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining an incredible community of innovators, entrepreneurs, and researchers driving the future of biotechnology and diagnostics...